IPO Plus

BSE · 532998

Lotus Eye Hospital And In

116.25
market cap
P/E
EPS
₹—
Book value
₹—
ROE
ROCE
1.06%
Debt / equity

Revenue & net profit by period

Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.

013.7227.4541.1754.89Mar 19Mar 20Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26
Revenue (₹ Cr) Net profit (₹ Cr)

Latest period: revenue ₹55 Cr with net profit ₹0 Cr — a 0.15% net margin, versus 1.45% the period before.

Shareholding

As of 2026-06-30

40.14%
promoter holding
  • Promoter40.14%
  • Public59.85%
  • DII0.02%

9,627 shareholders on record

Promoter holding trend

Each disclosed period, oldest to newest

40.03%40.14%Sep 24Jun 26

52-week position

Where the current price sits in its yearly band

97.6116153

The band spans 1.57× from low to high.

Risk flags

Derived from disclosed data

No flags raised by the data.

Peer comparison

Medical Care Facilities · ranked #3 of 3 by market cap · medians across 2 industry peers

P/E
vs 22.93 peer med
P/B
vs 4.72 peer med
ROE %
vs 20.24 peer med
Margin %
vs 10.98 peer med
CompanyMkt capP/EP/BROEMargin
Indraprastha Medical Corporation Ltd.₹3,309 Cr17.64.4824.8%12.34%
GPT Healthcare Limited₹1,336 Cr28.264.9615.67%9.61%
Lotus Eye Hospital & Institute Ltd.(this company)₹239 Cr1437.134.020.13%0.26%

AI analysis

AI-generated · google/gemini-2.5-flash

Lotus Eye Hospital & Institute Ltd. is listed with a market capitalization of Rs 253 Cr. The company reported revenue of Rs 50.86 Cr and an EPS of Rs 0.04. The debt-to-equity ratio stands at 0.04.

Positives

  • +The company's debt-to-equity ratio is low at 0.04.
  • +Return on equity (ROE) is 13.4% as of the latest annual data.

Negatives

  • Promoter pledging is high, with 87.15% of promoter shares pledged as of June 30, 2026.
  • The company recorded a net loss of Rs -0.32 Cr in the quarter ending March 2026.
  • The company is under LT-ASM surveillance, indicating regulatory attention.
  • The price-to-earnings (P/E) ratio is high at 194.17.
  • Return on Capital Employed (ROCE) is low at 1.0589%.

Financial performance

For the financial year ending March 2025, revenue was Rs 50.86 Cr, with a net profit of Rs 0.7393 Cr. This follows a revenue of Rs 49.5126 Cr and a net profit of Rs 2.9145 Cr in March 2024. Quarterly revenue for March 2026 was Rs 13.61 Cr, resulting in a net loss of Rs -0.32 Cr.

Profitability & returns

The company recorded a profit margin of 14.9%. Return on equity (ROE) was 13.4%, and return on capital employed (ROCE) was 1.0589%. The earnings per share (EPS) for the latest available annual period was Rs 0.04.

Balance sheet

Lotus Eye Hospital & Institute Ltd. has a low debt-to-equity ratio of 0.04. The book value per share is Rs 28.92. There are no dividend payouts reported, with the dividend yield at 0%.

Ownership & pledges

As of June 30, 2026, promoter holding was 40.1373%, with public shareholding at 59.8471%. DIIs held 0.0156% of shares, with no FII holding. A significant portion of promoter shares, 87.15%, is pledged. The number of shareholders was 9627.

Regulatory & surveillance

The company is currently under LT-ASM surveillance, specifically ASM Stage 1. This includes measures such as LT-ASM.

Data as of — price: 2026-09-23 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.

How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.

Back to Lotus Eye Hospital And Inshare price & fundamentals

Telegram App